Cargando…

Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil

INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online surve...

Descripción completa

Detalles Bibliográficos
Autores principales: Fares, Aline F., Martinez, Pedro H., Farina, Pedro H., Bicalho de Souza, Isaac, Araújo, Daniel V., Paiva, Narayana S., Orlando, Ligia F., Colombo, Tatiana Elias, Mascarenhas, Eldsamira, Gelatti, Ana Caroline Z., Baldotto, Clarissa, Zukin, Mauro, Araujo, Luiz Henrique, Mathias, Clarissa, Werutsky, Gustavo, de Castro, Gilberto, Cordeiro de Lima, Vladmir C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526154/
https://www.ncbi.nlm.nih.gov/pubmed/36193188
http://dx.doi.org/10.1016/j.jtocrr.2022.100402
_version_ 1784800815838396416
author Fares, Aline F.
Martinez, Pedro H.
Farina, Pedro H.
Bicalho de Souza, Isaac
Araújo, Daniel V.
Paiva, Narayana S.
Orlando, Ligia F.
Colombo, Tatiana Elias
Mascarenhas, Eldsamira
Gelatti, Ana Caroline Z.
Baldotto, Clarissa
Zukin, Mauro
Araujo, Luiz Henrique
Mathias, Clarissa
Werutsky, Gustavo
de Castro, Gilberto
Cordeiro de Lima, Vladmir C.
author_facet Fares, Aline F.
Martinez, Pedro H.
Farina, Pedro H.
Bicalho de Souza, Isaac
Araújo, Daniel V.
Paiva, Narayana S.
Orlando, Ligia F.
Colombo, Tatiana Elias
Mascarenhas, Eldsamira
Gelatti, Ana Caroline Z.
Baldotto, Clarissa
Zukin, Mauro
Araujo, Luiz Henrique
Mathias, Clarissa
Werutsky, Gustavo
de Castro, Gilberto
Cordeiro de Lima, Vladmir C.
author_sort Fares, Aline F.
collection PubMed
description INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online survey assessing CGP use and treating physicians’ confidence, composed of three self-confidence domains, which are as follows: confidence in interpreting CGP results, confidence in treating oncogenic-driven LUAD, and confidence in managing tyrosine kinase inhibitor adverse events. The survey was distributed to medical oncologists who treat lung cancer in Brazil. Comparisons between groups were performed using the chi-square or Fisher’s exact test. Univariable and multivariable (adjusted OR) analyses were performed. RESULTS: Among 104 respondents who treat patients with lung cancer, 55% were from the Southeast region, 28% had high lung cancer clinical load, and 33% had in-house molecular testing. More than half (51%) of the participants request CGP systematically to stage IV LUAD. As for provider confidence, 67% stated being confident in all three domains: 76% confident in interpreting CGP, 84% confident in treating oncogenic-driven LUAD, and 81% in managing tyrosine kinase inhibitor adverse events. Providers’ confidence was associated with systematically requesting CGP to stage IV LUAD (p = 0.013). After controlling for the variables of interest, systematic requesting CGP for stage IV LUAD revealed a significant association with the provider’s confidence (adjusted OR = 0.35, p = 0.028, 95% CI: 0.14–0.84). The major challenge for properly requesting CGP was the long turnaround time and the fear of treatment delays. CONCLUSIONS: Even though CGP for stage IV LUAD in Brazil is fully sponsored, only half of the oncologists in our survey systematically request it.. Requesting CGP was associated with providers’ confidence. Improving access and promoting providers’ awareness of CGP utility is necessary to increase CGP use and better inform treatment decisions.
format Online
Article
Text
id pubmed-9526154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95261542022-10-02 Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil Fares, Aline F. Martinez, Pedro H. Farina, Pedro H. Bicalho de Souza, Isaac Araújo, Daniel V. Paiva, Narayana S. Orlando, Ligia F. Colombo, Tatiana Elias Mascarenhas, Eldsamira Gelatti, Ana Caroline Z. Baldotto, Clarissa Zukin, Mauro Araujo, Luiz Henrique Mathias, Clarissa Werutsky, Gustavo de Castro, Gilberto Cordeiro de Lima, Vladmir C. JTO Clin Res Rep Original Article INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online survey assessing CGP use and treating physicians’ confidence, composed of three self-confidence domains, which are as follows: confidence in interpreting CGP results, confidence in treating oncogenic-driven LUAD, and confidence in managing tyrosine kinase inhibitor adverse events. The survey was distributed to medical oncologists who treat lung cancer in Brazil. Comparisons between groups were performed using the chi-square or Fisher’s exact test. Univariable and multivariable (adjusted OR) analyses were performed. RESULTS: Among 104 respondents who treat patients with lung cancer, 55% were from the Southeast region, 28% had high lung cancer clinical load, and 33% had in-house molecular testing. More than half (51%) of the participants request CGP systematically to stage IV LUAD. As for provider confidence, 67% stated being confident in all three domains: 76% confident in interpreting CGP, 84% confident in treating oncogenic-driven LUAD, and 81% in managing tyrosine kinase inhibitor adverse events. Providers’ confidence was associated with systematically requesting CGP to stage IV LUAD (p = 0.013). After controlling for the variables of interest, systematic requesting CGP for stage IV LUAD revealed a significant association with the provider’s confidence (adjusted OR = 0.35, p = 0.028, 95% CI: 0.14–0.84). The major challenge for properly requesting CGP was the long turnaround time and the fear of treatment delays. CONCLUSIONS: Even though CGP for stage IV LUAD in Brazil is fully sponsored, only half of the oncologists in our survey systematically request it.. Requesting CGP was associated with providers’ confidence. Improving access and promoting providers’ awareness of CGP utility is necessary to increase CGP use and better inform treatment decisions. Elsevier 2022-08-30 /pmc/articles/PMC9526154/ /pubmed/36193188 http://dx.doi.org/10.1016/j.jtocrr.2022.100402 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Fares, Aline F.
Martinez, Pedro H.
Farina, Pedro H.
Bicalho de Souza, Isaac
Araújo, Daniel V.
Paiva, Narayana S.
Orlando, Ligia F.
Colombo, Tatiana Elias
Mascarenhas, Eldsamira
Gelatti, Ana Caroline Z.
Baldotto, Clarissa
Zukin, Mauro
Araujo, Luiz Henrique
Mathias, Clarissa
Werutsky, Gustavo
de Castro, Gilberto
Cordeiro de Lima, Vladmir C.
Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title_full Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title_fullStr Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title_full_unstemmed Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title_short Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
title_sort assessing oncologists’ attitudes concerning comprehensive genomic profiling in stage iv lung adenocarcinoma in brazil
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526154/
https://www.ncbi.nlm.nih.gov/pubmed/36193188
http://dx.doi.org/10.1016/j.jtocrr.2022.100402
work_keys_str_mv AT faresalinef assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT martinezpedroh assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT farinapedroh assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT bicalhodesouzaisaac assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT araujodanielv assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT paivanarayanas assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT orlandoligiaf assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT colombotatianaelias assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT mascarenhaseldsamira assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT gelattianacarolinez assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT baldottoclarissa assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT zukinmauro assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT araujoluizhenrique assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT mathiasclarissa assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT werutskygustavo assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT decastrogilberto assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil
AT cordeirodelimavladmirc assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil